Since 2019, numerous RCTs have investigated novel therapeutic agents for HF, including angiotensin receptor–neprilysin inhibitors (ARNIs), sodium–glucose cotransporter 2 (SGLT2) inhibitors, and ivabradine. This evidence concerns the gene SLC5A2 and hydrops fetalis.